<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268836</url>
  </required_header>
  <id_info>
    <org_study_id>OAC #001</org_study_id>
    <nct_id>NCT04268836</nct_id>
  </id_info>
  <brief_title>Vision Improvement for Patients With Age-Related Macular Degeneration</brief_title>
  <acronym>AMD</acronym>
  <official_title>Vision Improvement for Patients With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Acuity Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bochner Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Optimal Acuity Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Optimal Acuity Clear-K® Low Vision Aid&#xD;
      System provides a safe and effective treatment to improve vision for patients with&#xD;
      age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Optimal Acuity Clear-K® Low Vision Aid System treats corneas with near infrared light in&#xD;
      order to change the modulus of small volumes of anterior stromal corneal tissue. The change&#xD;
      of modulus produces a change of corneal stiffness and shape that modifies the distribution of&#xD;
      light onto the retina. Light rays are redirected from dysfunctional areas of the retina that&#xD;
      have been damaged by age-related macular degeneration (AMD) to functional areas of the&#xD;
      retina, thereby improving patient vision.&#xD;
&#xD;
      200 AMD patients meeting eligibility requirements will be treated. The study will record and&#xD;
      analyze pre-treatment (Tx) and post-Tx examinations with follow-up extending to 24 months&#xD;
      post-Tx. Analysis will include descriptive statistics and measures of correlation between&#xD;
      outcomes and patient baseline characteristics.&#xD;
&#xD;
      The primary objective of the study is to evaluate the safety and effectiveness of Clear-K®&#xD;
      treatment in providing vision improvement to AMD patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomized, unmasked clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best spectacle-corrected distance visual acuity (CDVA) changes from baseline to 24 months post-Tx</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>CDVA will be measured using ETDRS letter scoring both pre-Tx and post-Tx with follow-up to 24 months post-Tx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Function Questionnaire (VFQ)-25 quality of life assessment</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The VFQ-25 instrument will be used to assess patient quality of life measures.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Acuity Clear-K® Low Vision Aid System treatment</intervention_name>
    <description>The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Any race&#xD;
&#xD;
          3. Patient is at least 50 years old.&#xD;
&#xD;
          4. Patient has diagnosed dry or wet age-related macular degeneration in one or both eyes,&#xD;
             as verified by a complete ocular examination by a retina specialist; the full ocular&#xD;
             examination, including optical coherence tomography (OCT) measurements, should be part&#xD;
             of the patient's file.&#xD;
&#xD;
          5. Wet AMD eyes should have an inactive disease state (i.e., there is no clinical or OCT&#xD;
             evidence of wet AMD disease activity).&#xD;
&#xD;
          6. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s)&#xD;
             to be treated..&#xD;
&#xD;
          7. Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D&#xD;
             in eye(s) to be treated.&#xD;
&#xD;
          8. Patient has moderate to severe vision impairment due to dry age-related macular&#xD;
             degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/80 or&#xD;
             worse (decimal = 0.25 or less; logMAR ≥ 0.60) in the better eye.&#xD;
&#xD;
          9. Patient has CDVA of 20/400 or better (decimal = 0.05 or greater; logMAR ≤ 1.30) in the&#xD;
             worse eye.&#xD;
&#xD;
         10. Patient has normal corneal surface topography on videokeratography (i.e., without&#xD;
             distorted or unclear corneal mires) in both eyes.&#xD;
&#xD;
         11. Patient is not a contact lens (CL) wearer.&#xD;
&#xD;
         12. Patient is willing and able to comply with all examinations.&#xD;
&#xD;
         13. Patient must be competent to sign an informed consent form before study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Corneal disease or disorder in either eye;&#xD;
&#xD;
          2. Corneal topographic astigmatism greater than 2.00 D (mean value within 3.0 mm optical&#xD;
             zone);&#xD;
&#xD;
          3. Pathological retinal morphology in either eye that completely affects the entire 10°&#xD;
             (3 mm diameter) of the retina centered on the foveola (as evaluated by optical&#xD;
             coherence tomography);&#xD;
&#xD;
          4. Potential Visual Acuity (PVA) in both eyes that is not improved by at least three&#xD;
             lines compared to CDVA;&#xD;
&#xD;
          5. Increased intraocular pressure (above 20 mm Hg), glaucoma or history of glaucoma; and&#xD;
&#xD;
          6. Presence or history of any other condition or finding that, in the opinion of the&#xD;
             investigator, makes the patient unsuitable as a candidate for study participation or&#xD;
             that may confound the outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Berry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Optimal Acuity Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Berry, PhD</last_name>
    <phone>8318691384</phone>
    <email>mberry177@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel Markowitz, MD, FRCSC</last_name>
    <phone>4165315425</phone>
    <email>snm1@rogers.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1929 Bayview Ave., Suite 117</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Samuel Markowitz, MD, FRCSC</last_name>
      <phone>4165315425</phone>
      <email>snm1@rogers.com</email>
    </contact>
    <investigator>
      <last_name>Samuel N Markowitz, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry AMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>neovascular AMD</keyword>
  <keyword>age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

